Research and Development Investment: Blueprint Medicines Corporation vs TG Therapeutics, Inc.

Biotech R&D: Blueprint vs. TG Therapeutics

__timestampBlueprint Medicines CorporationTG Therapeutics, Inc.
Wednesday, January 1, 20143184400031354781
Thursday, January 1, 20154858800043445817
Friday, January 1, 20168113100066489820
Sunday, January 1, 201714468700096886134
Monday, January 1, 2018243621000153793000
Tuesday, January 1, 2019331450000148369000
Wednesday, January 1, 2020326860000151934000
Friday, January 1, 2021601033000198532000
Saturday, January 1, 2022477419000112128000
Sunday, January 1, 202342772000076192000
Monday, January 1, 2024341433000
Loading chart...

Igniting the spark of knowledge

A Decade of Innovation: R&D Investments in Biotech

In the ever-evolving landscape of biotechnology, research and development (R&D) investments are the lifeblood of innovation. Over the past decade, Blueprint Medicines Corporation and TG Therapeutics, Inc. have demonstrated contrasting trajectories in their R&D expenditures.

Blueprint Medicines Corporation: A Steady Climb

Since 2014, Blueprint Medicines has consistently increased its R&D spending, peaking in 2021 with a remarkable 1,790% increase from its 2014 levels. This surge underscores the company's commitment to pioneering new therapies and expanding its pipeline.

TG Therapeutics, Inc.: A More Modest Approach

Conversely, TG Therapeutics has adopted a more conservative strategy, with R&D expenses growing by approximately 150% over the same period. Despite this, the company has made significant strides in its niche, focusing on targeted therapies.

As these two biotech giants continue to innovate, their R&D investments will undoubtedly shape the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025